{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Song F"],"funding":["Shanghai Municipal Health Commission Collaborative Innovation Cluster Project","Shanghai Municipal Health Commission","Fudan University","Postgraduate Research & Practice Innovation Program of Jiangsu Province","National Natural Science Foundation of China","Jiangsu Provincial Research Hospital","Shanghai Science and Technology Commission","Eastern Talent Program (Leading project)","Shanghai hospital development center","Science Foundation of Zhongshan Hospital"],"pagination":["e1738"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11296886"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(8)"],"pubmed_abstract":["<h4>Background</h4>The therapeutic potential of immune checkpoint blockade (ICB) extends across various cancers; however, its effectiveness in treating hepatocellular carcinoma (HCC) is frequently curtailed by both inherent and developed resistance.<h4>Objective</h4>This research explored the effectiveness of integrating anlotinib (a broad-spectrum tyrosine kinase inhibitor) with programmed death-1 (PD-1) blockade and offers mechanistic insights into more effective strategies for treating HCC.<h4>Methods</h4>Using patient-derived organotypic tissue spheroids and orthotopic HCC mouse models, we assessed the effectiveness of anlotinib combined with PD-1 blockade. The impact on the tumour immune microenvironment and underlying mechanisms were assessed using time-of-flight mass cytometry, RNA "],"journal":["Clinical and translational medicine"],"pubmed_title":["Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8<sup>+</sup> T-cell infiltration in hepatocellular carcinoma."],"pmcid":["PMC11296886"],"funding_grant_id":["YJXYY202204-YSB07","2022LJ005","22140900600","82072715","82341027","22S31901800","2021ZSCX28","201940075","21140900300","2020ZSLC31","KYCX23_3423","SHDC2023CRD025","2019CXJQ02"],"pubmed_authors":["Wang CG","Sun HX","Wang PX","Guo W","Song F","Hu B","Wang TL","Fan J","Chen Z","Yang XR","Cheng JW","Tang PJ","Liang XL","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8<sup>+</sup> T-cell infiltration in hepatocellular carcinoma.","description":"<h4>Background</h4>The therapeutic potential of immune checkpoint blockade (ICB) extends across various cancers; however, its effectiveness in treating hepatocellular carcinoma (HCC) is frequently curtailed by both inherent and developed resistance.<h4>Objective</h4>This research explored the effectiveness of integrating anlotinib (a broad-spectrum tyrosine kinase inhibitor) with programmed death-1 (PD-1) blockade and offers mechanistic insights into more effective strategies for treating HCC.<h4>Methods</h4>Using patient-derived organotypic tissue spheroids and orthotopic HCC mouse models, we assessed the effectiveness of anlotinib combined with PD-1 blockade. The impact on the tumour immune microenvironment and underlying mechanisms were assessed using time-of-flight mass cytometry, RNA ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-18T20:22:31.031Z","creation":"2025-02-19T02:27:08.412Z"},"accession":"S-EPMC11296886","cross_references":{"pubmed":["39095323"],"doi":["10.1002/ctm2.1738"]}}